Blueprint Medicines price target raised to $66 from $65 at Needham

Needham analyst Ami Fadia raised the firm’s price target on Blueprint Medicines to $66 from $65 and keeps a Buy rating on the shares. The analyst is citing a survey of 20 physicians who treat, on average, 28 indolent systemic mastocytosis – or ISM – patients each. The physicians aware of Blueprint’s Ayvakit are prescribing it to 23% of their ISM patients, and they anticipate that the number of ISM patients on Ayvakit will grow 47% in the next 6 months and 73% over the next year, the firm tells investors in a research note, adding that the consensus for the second half of the year is achievable.